# MOMA Therapeutics

> MOMA Therapeutics is a Cambridge, Massachusetts biotech building precision small-molecule medicines against 'molecular machines' - the highly dynamic, shape-shifting enzymes (ATPases, GTPases and related proteins) that power cellular processes and underlie cancer and other diseases. Spun out of Third Rock Ventures in 2020 by four academic leaders in protein biophysics and structural biology, MOMA's proprietary KNOMATIC platform fuses deep structural insight, advanced hit-finding (fragment and DNA-encoded library screening) and machine-learning-driven lead optimization to drug targets long considered intractable. The company has raised about $236M, advanced its first oncology program into the clinic, and partnered with Roche and Bayer.

- **Founded:** 2020
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Dorothee Kern (Scientific Founder (protein biophysics & motion, HHMI / Brandeis University)), Eva Nogales (Scientific Founder (cryo-EM & structural biology, HHMI / UC Berkeley)), Johannes Walter (Scientific Founder (molecular machines & genome maintenance, HHMI / Harvard Medical School)), Timur Yusufzai (Founder (former Third Rock Entrepreneur-in-Residence; ex-Harvard Medical School))
- **Team size:** ~45 employees
- **Products:** KNOMATIC platform, Precision oncology pipeline, Partnered discovery programs
- **Notable:** Launched in 2020 with $86M from Third Rock Ventures to target molecular machines, Raised a $150M Series B in May 2022, bringing total funding to roughly $236M, Advanced its first oncology program into Phase 1 clinical trials by 2024

## Products & services

- **KNOMATIC platform** — Proprietary, integrated drug-discovery engine combining deep structural insight, advanced hit-finding (high-throughput fragment screening and DNA-encoded library screening) and computation- and machine-learning-enabled lead optimization to drug families of highly dynamic proteins.
- **Precision oncology pipeline** — A wholly owned pipeline of small-molecule precision cancer programs targeting molecular machines; the lead program advanced into Phase 1 clinical testing.
- **Partnered discovery programs** — Discovery collaborations applying KNOMATIC to partner-selected targets, including agreements with Roche and Bayer.

## Achievements

- Launched in 2020 with $86M from Third Rock Ventures to target molecular machines
- Raised a $150M Series B in May 2022, bringing total funding to roughly $236M
- Advanced its first oncology program into Phase 1 clinical trials by 2024
- Signed discovery and license partnerships with both Roche and Bayer
- Founded by four prominent academic leaders, three of them HHMI investigators

## Latest updates

- **2024-10** — Entered an option and exclusive license agreement with Bayer to develop and commercialize a small-molecule oncology program based on the KNOMATIC platform.
- **2024-01** — Lead oncology program advanced into Phase 1 clinical trials; a second asset anticipated to follow.
- **2022-05** — Closed $150M Series B led by Goldman Sachs Asset Management to push precision cancer drugs toward the clinic.

## Links

- Website: https://momatx.com
- LinkedIn: https://www.linkedin.com/company/momatx
- Twitter/X: https://twitter.com/moma_tx

---

Profile page: https://yespress.io/moma-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-13